SCHEMBL29434792

SCHEMBL29434792

Cc1c(Cl)cccc1S(=O)(=O)Nc1c(F)cc(C#Cc2cccc(F)c2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.45
EDNRB P24530 2/20 0.44
EDNRA P25101 2/20 0.44
CA12 O43570 3/20 0.43
CA2 P00918 3/20 0.43
CA9 Q16790 3/20 0.43
SLC40A1 Q9NP59 2/20 0.41
CA1 P00915 2/20 0.41
CCR4 P51679 1/20 0.39
PTGES2 Q9H7Z7 3/20 0.39
CCR2 P41597 1/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SLC6A2 P23975 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22980330 1.00 HSD11B1 (0.45) HSD11B1EDNRBEDNRACA12CA2
SCHEMBL29434879 0.91 HSD11B1 (0.45) HSD11B1EDNRBEDNRASLC40A1CCR4
SCHEMBL22980410 0.91 HSD11B1 (0.45) HSD11B1EDNRBEDNRASLC40A1CCR4
SCHEMBL22980994 0.91 HSD11B1 (0.47) HSD11B1EDNRBEDNRASLC40A1CCR4
SCHEMBL22980484 0.87 SMN1; SMN2 (0.49) HSD11B1EDNRBEDNRACA12CA2
SCHEMBL22980440 0.87 HSD11B1 (0.45) HSD11B1EDNRBEDNRASLC40A1CCR4
SCHEMBL29434864 0.87 HSD11B1 (0.45) HSD11B1EDNRBEDNRASLC40A1CCR4
SCHEMBL29434828 0.87 SMN1; SMN2 (0.49) HSD11B1EDNRBEDNRACA12CA2
SCHEMBL24467922 0.86 HSD11B1 (0.47) HSD11B1EDNRBEDNRASLC40A1CCR4
SCHEMBL24467921 0.84 EDNRA (0.49) HSD11B1EDNRBEDNRASLC40A1CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013495-A1 ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS F. Hoffmann-La Roche AG (CH) 2022-06-22 EP claimed
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN claimed
US-12065399-B2 Arylsulfonamide derivatives HOFFMANN-LA ROCHE INC. (US) 2024-08-20 US disclosed
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2022-06-02 US disclosed
CN-114174266-A Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators 豪夫迈·罗氏有限公司 2022-03-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169599-A1 ARYLSULFONAMIDE DERIVATIVES ARSA, SULT1E1, STS HSD11B1 1242/4885EDNRB 1400/4885EDNRA 1982/4885
US-12065399-B2 Arylsulfonamide derivatives ARSA, SULT1E1, STS HSD11B1 1242/4885EDNRB 1400/4885EDNRA 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.